Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline maintenance after ketamine response in depressive disorder
2012-002954-21Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of minocycline and ketamine in major depressive disorder (MDD) and Bipolar II disorder (BP-II) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of subjects who survive relapse-free among responders. Started Mar 2013; status: terminated.
02
Drugs
minocyclineketamine
03
Conditions
major depressive disorder (MDD)Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on 2012-002954-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002954-21.